Skip to main content
Top
Appendix
Available only for authorised users
Literature
1.
go back to reference Fekrvand S, Yazdani R, Olbrich P, Gennery A, Rosenzweig SD, Condino-Neto A, et al. Primary immunodeficiency diseases and Bacillus Calmette-Guérin (BCG)-vaccine-derived complications: a systematic review. J Allergy Clin Immunol Pract United States. 2020;8:1371–86.CrossRef Fekrvand S, Yazdani R, Olbrich P, Gennery A, Rosenzweig SD, Condino-Neto A, et al. Primary immunodeficiency diseases and Bacillus Calmette-Guérin (BCG)-vaccine-derived complications: a systematic review. J Allergy Clin Immunol Pract United States. 2020;8:1371–86.CrossRef
2.
go back to reference Yehia L, Keel E, Eng C. The clinical spectrum of PTEN mutations. Annu Rev Med Annual Reviews. 2020;71:103–16.CrossRef Yehia L, Keel E, Eng C. The clinical spectrum of PTEN mutations. Annu Rev Med Annual Reviews. 2020;71:103–16.CrossRef
3.
go back to reference Taylor H, Laurence ADJ, Uhlig HH. The role of PTEN in innate and adaptive immunity. Cold Spring Harb Perspect Med. 2019;9(12):a036996.CrossRef Taylor H, Laurence ADJ, Uhlig HH. The role of PTEN in innate and adaptive immunity. Cold Spring Harb Perspect Med. 2019;9(12):a036996.CrossRef
4.
go back to reference Chen HH, Händel N, Ngeow J, Muller J, Hühn M, Yang HT, et al. Immune dysregulation in patients with PTEN hamartoma tumor syndrome: analysis of FOXP3 regulatory T cells. J Allergy Clin Immunol Elsevier. 2017;139:607-620.e15.CrossRef Chen HH, Händel N, Ngeow J, Muller J, Hühn M, Yang HT, et al. Immune dysregulation in patients with PTEN hamartoma tumor syndrome: analysis of FOXP3 regulatory T cells. J Allergy Clin Immunol Elsevier. 2017;139:607-620.e15.CrossRef
5.
go back to reference Heindl M, Handel N, Ngeow J, Kionke J, Wittekind C, Kamprad M, et al. Autoimmunity, intestinal lymphoid hyperplasia, and defects in mucosal B-cell homeostasis in patients with PTEN hamartoma tumor syndrome. Gastroenterology United States. 2012;142:1093-1096.e6. Heindl M, Handel N, Ngeow J, Kionke J, Wittekind C, Kamprad M, et al. Autoimmunity, intestinal lymphoid hyperplasia, and defects in mucosal B-cell homeostasis in patients with PTEN hamartoma tumor syndrome. Gastroenterology United States. 2012;142:1093-1096.e6.
6.
go back to reference Taylor H, Yerlioglu D, Phen C, Ballauff A, Nedelkopolou N, Spier I, et al. mTOR inhibitors reduce enteropathy, intestinal bleeding and colectomy rate in juvenile polyposis of infancy due to PTEN-BMPR1A deletion syndrome. Hum Mol Genet. 2021;30(14):1273. Taylor H, Yerlioglu D, Phen C, Ballauff A, Nedelkopolou N, Spier I, et al. mTOR inhibitors reduce enteropathy, intestinal bleeding and colectomy rate in juvenile polyposis of infancy due to PTEN-BMPR1A deletion syndrome. Hum Mol Genet. 2021;30(14):1273.
7.
go back to reference Garcia-Prat M, Álvarez-Sierra D, Aguiló-Cucurull A, Salgado-Perandrés S, Briongos-Sebastian S, Franco-Jarava C, et al. Extended immunophenotyping reference values in a healthy pediatric population. Cytom Part B Clin Cytom John Wiley & Sons, Ltd. 2019;96:223–33.CrossRef Garcia-Prat M, Álvarez-Sierra D, Aguiló-Cucurull A, Salgado-Perandrés S, Briongos-Sebastian S, Franco-Jarava C, et al. Extended immunophenotyping reference values in a healthy pediatric population. Cytom Part B Clin Cytom John Wiley & Sons, Ltd. 2019;96:223–33.CrossRef
8.
go back to reference Garcia-Prat M, Vila-Pijoan G, Martos Gutierrez S, Gala Yerga G, García Guantes E, Martínez-Gallo M, et al. Age-specific pediatric reference ranges for immunoglobulins and complement proteins on the OptiliteTM automated turbidimetric analyzer. J Clin Lab Anal Wiley Online Library. 2018;32:e22420.CrossRef Garcia-Prat M, Vila-Pijoan G, Martos Gutierrez S, Gala Yerga G, García Guantes E, Martínez-Gallo M, et al. Age-specific pediatric reference ranges for immunoglobulins and complement proteins on the OptiliteTM automated turbidimetric analyzer. J Clin Lab Anal Wiley Online Library. 2018;32:e22420.CrossRef
9.
go back to reference Tsujita Y, Mitsui-Sekinaka K, Imai K, Yeh TW, Mitsuiki N, Asano T, et al. Phosphatase and tensin homolog (PTEN) mutation can cause activated phosphatidylinositol 3-kinase δ syndrome–like immunodeficiency. J Allergy Clin Immunols Elsevier Inc. 2016;138:1672–80.CrossRef Tsujita Y, Mitsui-Sekinaka K, Imai K, Yeh TW, Mitsuiki N, Asano T, et al. Phosphatase and tensin homolog (PTEN) mutation can cause activated phosphatidylinositol 3-kinase δ syndrome–like immunodeficiency. J Allergy Clin Immunols Elsevier Inc. 2016;138:1672–80.CrossRef
10.
go back to reference Tangye SG, Al-Herz W, Bousfiha A, Chatila T, Cunningham-Rundles C, Etzioni A, et al. Human inborn errors of immunity: 2019 Update on the Classification from the International Union of Immunological Societies Expert Committee. J Clin Immunol. 2020;40:24–64. Tangye SG, Al-Herz W, Bousfiha A, Chatila T, Cunningham-Rundles C, Etzioni A, et al. Human inborn errors of immunity: 2019 Update on the Classification from the International Union of Immunological Societies Expert Committee. J Clin Immunol. 2020;40:24–64.
11.
go back to reference Coulter TI, Chandra A, Bacon CM, Babar J, Curtis J, Screaton N, et al. Clinical spectrum and features of activated phosphoinositide 3-kinase & #x3b4; syndrome: A large patient cohort study. J Allergy Clin Immunol Elsevier. 2017;139:597-606.e4.CrossRef Coulter TI, Chandra A, Bacon CM, Babar J, Curtis J, Screaton N, et al. Clinical spectrum and features of activated phosphoinositide 3-kinase & #x3b4; syndrome: A large patient cohort study. J Allergy Clin Immunol Elsevier. 2017;139:597-606.e4.CrossRef
12.
go back to reference Elkaim E, Neven B, Bruneau J, Mitsui-Sekinaka K, Stanislas A, Heurtier L, et al. Clinical and immunologic phenotype associated with activated phosphoinositide 3-kinase & #x3b4; syndrome 2: A cohort study. J Allergy Clin Immunol Elsevier. 2016;138:210-218.e9.CrossRef Elkaim E, Neven B, Bruneau J, Mitsui-Sekinaka K, Stanislas A, Heurtier L, et al. Clinical and immunologic phenotype associated with activated phosphoinositide 3-kinase & #x3b4; syndrome 2: A cohort study. J Allergy Clin Immunol Elsevier. 2016;138:210-218.e9.CrossRef
13.
go back to reference Nunes-Santos CJ, Rosenzweig SD. Bacille Calmette-Guerin complications in newly described primary immunodeficiency Diseases: 2010–2017. Front Immunol Frontiers. 2018;9:1423. Nunes-Santos CJ, Rosenzweig SD. Bacille Calmette-Guerin complications in newly described primary immunodeficiency Diseases: 2010–2017. Front Immunol Frontiers. 2018;9:1423.
14.
go back to reference Chiriaco M, Brigida I, Ariganello P, Di Cesare S, Di Matteo G, Taus F, et al. The case of an APDS patient: defects in maturation and function and decreased in vitro anti-mycobacterial activity in the myeloid compartment. Clin Immunol. 2017;178:20–8.CrossRef Chiriaco M, Brigida I, Ariganello P, Di Cesare S, Di Matteo G, Taus F, et al. The case of an APDS patient: defects in maturation and function and decreased in vitro anti-mycobacterial activity in the myeloid compartment. Clin Immunol. 2017;178:20–8.CrossRef
15.
go back to reference Sloot YJE, Rabold K, Netea MG, Smit JWA, Hoogerbrugge N, Netea-Maier RT. Effect of PTEN inactivating germline mutations on innate immune cell function and thyroid cancer-induced macrophages in patients with PTEN hamartoma tumor syndrome. Oncogene Nature Publishing Group. 2019;38(19):3743–55. Sloot YJE, Rabold K, Netea MG, Smit JWA, Hoogerbrugge N, Netea-Maier RT. Effect of PTEN inactivating germline mutations on innate immune cell function and thyroid cancer-induced macrophages in patients with PTEN hamartoma tumor syndrome. Oncogene Nature Publishing Group. 2019;38(19):3743–55.
16.
go back to reference Huang GC, Redelman-Sidi G, Rosen N, Glickman MS, Jiang XJ. Inhibition of mycobacterial infection by the tumor suppressor PTEN. J Biol Chem. 2012;287:23196–202.CrossRef Huang GC, Redelman-Sidi G, Rosen N, Glickman MS, Jiang XJ. Inhibition of mycobacterial infection by the tumor suppressor PTEN. J Biol Chem. 2012;287:23196–202.CrossRef
17.
go back to reference Rosain J, Kong X-F, Martinez-Barricarte R, Oleaga-Quintas C, Ramirez-Alejo N, Markle J, et al. Mendelian susceptibility to mycobacterial disease: 2014–2018 update. Immunol Cell Biol. 2019;97:360–7.CrossRef Rosain J, Kong X-F, Martinez-Barricarte R, Oleaga-Quintas C, Ramirez-Alejo N, Markle J, et al. Mendelian susceptibility to mycobacterial disease: 2014–2018 update. Immunol Cell Biol. 2019;97:360–7.CrossRef
Metadata
Title
BCG Vaccine–Associated Complications in Patients with PTEN Hamartoma Tumor Syndrome
Authors
Henry Taylor
Dominik Aschenbrenner
Mike Thomson
Hannah Chen
Holm H. Uhlig
Publication date
01-10-2021
Publisher
Springer US
Published in
Journal of Clinical Immunology / Issue 7/2021
Print ISSN: 0271-9142
Electronic ISSN: 1573-2592
DOI
https://doi.org/10.1007/s10875-021-01100-9

Other articles of this Issue 7/2021

Journal of Clinical Immunology 7/2021 Go to the issue